1. NLRC5 Functions beyond MHC I Regulation—What Do We Know So Far?
    Szilvia Benkő et al, 2017, Front. Immunol. CrossRef
  2. NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
    Sayuri Yoshihama et al, 2017, Trends Cancer CrossRef
  3. High Expression of NLRC5 is associated with prognosis of gastric cancer
    Yuemei Li et al, 2018 CrossRef
  4. Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway.
    Zheqi Zong et al, 2019, J Cell Mol Med CrossRef
  5. null
    Barbara Seliger et al, 2020 CrossRef
  6. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies
    B. Seliger, 2016, HLA CrossRef
  7. null
    S.T. Chelbi et al, 2017 CrossRef
  8. Emerging Roles for NLRC5 in Immune Diseases
    Jie-quan Wang et al, 2019, Front. Pharmacol. CrossRef
  9. NLRC5: new cancer buster?
    Feng Tang et al, 2020, Mol Biol Rep CrossRef
  10. Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
    Daan P. Hurkmans et al, 2020, Cancer Immunol Immunother CrossRef
  11. MHC class I transactivator NLRC5 in host immunity, cancer and beyond
    Steven X. Cho et al, 2020, Immunology CrossRef
  12. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
    Akhil Shukla et al, 2021, IJMS CrossRef
  13. Inhibition of NLRC5 attenuates the malignant growth and enhances the sensitivity of gastric cancer cells to 5‑FU chemotherapy by blocking the carcinogenic effect of YY1
    Shan Liang et al, 2022, Exp Ther Med CrossRef
  14. NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer
    Yu Dong et al, 2022, Bioengineered CrossRef
  15. NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity
    Madanraj Appiya Santharam et al, 2023, IJMS CrossRef
  16. NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens
    Galaxia M. Rodriguez et al, 2024, Front. Immunol. CrossRef